Integrated BioPharma Q2 revenue down 10.3%, swings to net loss of $0.8M

INTEGRATED BIOPHARMA INC

2026-Q2 EPS reported -$0.02 revenue$23,969,000

Revenue $11.3M vs $12.6M Q2 prior year; operating loss $0.9M vs income $0.2M.
Net loss $0.8M vs net income $0.1M; diluted EPS $(0.03) vs $0.00.
Six-month revenue $24.0M vs $26.2M; operating loss $0.7M vs income $0.7M.
Two largest contract manufacturing customers accounted for ~89% of total revenue.
Selling and administrative expenses decreased slightly to $0.9M from $1.0M.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.